P16 Expression in carcinoma of unknown primary: Diagnostic indicator and prognostic marker

Head and Neck

Volumn 35, Issue 11, 2013, Pages 1521-1526

  Vent, Julia ^a   Haidle, Bastian ^a   Wedemeyer, Inga ^a   Huebbers, Christian ^b   Siefer, Oliver ^b   Semrau, Robert ^a   Preuss, Simon F ^a   Klussmann, Jens ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Jean Uhrmacher Institute for Otorhinolaryngological Research   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

carcinoma of unknown primary (CUP); identification of primary cancer; oropharynx; p16 EGFR; prognosis

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; TUMOR MARKER; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HEAD AND NECK DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; NECK METASTASIS; NECK TUMOR; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; TONSILLECTOMY; WART VIRUS;

CARCINOMA OF UNKNOWN PRIMARY (CUP); IDENTIFICATION OF PRIMARY CANCER; OROPHARYNX; P16 / EGFR; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CHEMORADIOTHERAPY; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NECK DISSECTION; NEOPLASM PROTEINS; NEOPLASMS, UNKNOWN PRIMARY; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886435744     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23190     Document Type: Article

References (31)

1. Adams JR, O'Brien CJ,. Unknown primary squamous cell carcinoma of the head and neck: a review of diagnosis, treatment and outcomes. Asian J Surg 2002; 25: 188-193.
2. Guntinas-Lichius O, Peter Klussmann J, Dinh S, et al. Diagnostic work-up and outcome of cervical metastases from an unknown primary. Acta Otolaryngol 2006; 126: 536-544.
3. Padovani D, Aimoni C, Zucchetta P, Paluzzi A, Pastore A,. 18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma. Eur Arch Otorhinolaryngol 2009; 266: 267-271.
4. Neben K, Hübner G, Folprecht G, Jäger D, Krämer A,. Metastases in the absence of a primary tumor: advances in the diagnosis and treatment of CUP syndrome. Dtsch Arztebl Int 2008; 105: 733-740.
5. Haas I, Hoffmann TK, Engers R, Ganzer U,. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol 2002; 259: 325-333.
6. Issing WJ, Taleban B, Tauber S,. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003; 260: 436-443.
7. Christiansen H, Hermann RM, Martin A, Nitsche M, Schmidberger H, Pradier O,. Neck lymph node metastases from an unknown primary tumor retrospective study and review of literature. Strahlenther Onkol 2005; 181: 355-362.
8. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA,. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg 2007; 194: 833-837; discussion 837-838.
9. Yabuki K, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G,. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol 2010; 267: 1785-1792.
10. Cerezo L, Raboso E, Ballesteros AI,. Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol 2011; 13: 88-97.
11. Kreimer AR, Clifford GM, Boyle P, Franceschi S,. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475.
12. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-1849.
13. Klussmann JP, Dinh S, Guntinas-Lichius O, et al. HPV-associated tonsillar cancer. An update. [Article in German] HNO 2004; 52: 208-218.
14. Gillison ML, Lowy DR,. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489.
15. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 2875-2884.
16. Haber DA,. Splicing into senescence: the curious case of p16 and p19ARF. Cell 1997; 91: 555-558.
17. Chung CH, Gillison ML,. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758-6762.
18. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
19. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
20. Klussmann JP, Gültekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-753.
21. Klussmann JP, Weissenborn SJ, Wieland U, et al. Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol 2003; 192: 129-132.
22. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
23. Hafkamp HC, Manni JJ, Speel EJ,. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 2004; 124: 520-526.
24. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656-2664.
25. Straetmans JM, Olthof N, Mooren JJ, de Jong J, Speel EJ, Kremer B,. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 2009; 119: 1951-1957.
26. Desai PC, Jaglal MV, Gopal P, et al. Human papillomavirus in metastatic squamous carcinoma from unknown primaries in the head and neck: a retrospective 7-year study. Exp Mol Pathol 2009; 87: 94-98.
27. Zhang MQ, El-Mofty SK, Dávila RM,. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer 2008; 114: 118-123.
28. Park JM, Jung CK, Choi YJ, et al. The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. Hum Pathol 2010; 41: 431-437.
29. Umudum H, Rezanko T, Dag F, Dogruluk T,. Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer 2005; 105: 171-177.
30. Weiss D, Koopmann M, Rudack C,. Prevalence and impact on clinicopathological characteristics of human papillomavirus-16 DNA in cervical lymph node metastases of head and neck squamous cell carcinoma. Head Neck 2011; 33: 856-862.
31. Specenier P, Vermorken JB,. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011; 11: 511-524.